Despite the proven efficacy of earlier treatments such as trastuzumab and pertuzumab in HER2-positive cancers, a substantial number of patients continue to exhibit disease progression, particularly in the CNS, underscoring the need for novel therapeutic options for this patient population. The gene discussed is ERBB2; the disease is cancer.